Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2022 Annual Meeting | Industry Therapeutic Update from Lundbeck: Clinical and Patient Perspectives

Monday 04/04/22
07:00 PM - 10:00 PM PDT Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
General Neurology
In this roundtable discussion, we will explore the burden and stigma that may be experienced by those living with a chronic condition, learn more about the efficacy and safety of VYEPTI® (eptinezumab-jjmr) and hear real patients share personal stories about living with the burden of a chronic condition and treatment with VYEPTI.
Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
0.00 credit

Program Materials Program Evaluations

Event Timeline
07:00 PM - 10:00 PM PDT Speaker Industry Therapeutic Update from Lundbeck: Clinical and Patient Perspectives
Faculty Disclosures
Andrew Charles, MD Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Charles has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Satsuma. Dr. Charles has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Finnegan. Dr. Charles has a non-compensated relationship as a Executive Board with American Headache Society that is relevant to AAN interests or activities.